melissaalvarez

Sodium-glucose cotransporter-2 inhibitors (SGLT-2) inhibitor use before the onset of COVID-19 infection is associated with a lower risk for COVID-19-related adverse outcomes in patients with diabetes.

Researchers evaluated the safety and efficacy of ensitrelvir for the treatment of mild to moderate COVID-19 infection during the Omicron wave.